Skip to main content
MABWELL (SHANGHAI) BIOSCIENCE CO., LTD. logo

MABWELL (SHANGHAI) BIOSCIENCE CO., LTD. — Investor Relations & Filings

Ticker · 688062 ISIN · CNE100005RD2 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 541 across all filing types
Latest filing 2023-04-06 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 688062

About MABWELL (SHANGHAI) BIOSCIENCE CO., LTD.

https://www.mabwell.com/en/

Mabwell (Shanghai) Bioscience Co., Ltd. is a biopharmaceutical enterprise focused on the discovery, development, and commercialization of therapeutic antibodies and innovative biologics. The company maintains an integrated R&D and manufacturing platform covering the full drug lifecycle, from target discovery and preclinical research to clinical development and commercial production. Its therapeutic pipeline addresses critical needs in oncology, autoimmune diseases, metabolic disorders, ophthalmology, and infectious diseases. Mabwell leverages proprietary technology platforms, including antibody-drug conjugates (ADCs), bispecific antibodies, and high-throughput screening, to develop a diverse portfolio of novel drug candidates and biosimilars. The organization is committed to delivering high-quality, accessible therapeutic solutions through its end-to-end biotechnological capabilities.

Recent filings

Filing Released Lang Actions
迈威生物2022年度审计报告
Audit Report / Information Classification · 95% confidence The document contains a detailed audit report including the auditor's opinion, basis for the opinion, key audit matters, responsibilities of management and auditors, and extensive financial statements such as consolidated balance sheets, income statements, cash flow statements, and notes. The presence of an auditor's report with a registration number, detailed audit procedures, and comprehensive financial data for the fiscal year 2022 indicates this is a full audited financial report. The document length is substantial (15,000 characters), and it includes actual financial statements and notes, not just an announcement or certification. Therefore, this document fits the definition of an Annual Report (10-K) or more precisely, an Audit Report / Information (AR) since it is primarily the audit report and audited financial statements rather than the full annual report narrative. Given the emphasis on the audit opinion and detailed audit procedures, the best classification is Audit Report / Information (AR). FY 2022
2023-04-06 Chinese
迈威生物2022年年度报告摘要
Annual Report Classification · 95% confidence The document is titled as the "2022 Annual Report Summary" of 迈威(上海)生物科技股份有限公司, indicating it is a summary of the full annual report. It contains detailed information about the company's business overview, risk factors, research and development pipeline, marketing, and financial data such as R&D expenses and product commercialization status. The document includes comprehensive management discussion and analysis, product pipeline details, and financial performance indicators for the fiscal year 2022. It also references the full annual report available on the Shanghai Stock Exchange website. The length of the document (15,000 characters) and the depth of content confirm it is the actual report, not just an announcement or a brief summary. Therefore, this document fits the definition of an Annual Report (10-K). FY 2022
2023-04-06 Chinese
迈威生物独立董事对公司对外担保情况的专项说明及独立意见
Audit Report / Information Classification · 90% confidence The document is a statement by independent directors regarding the company's external guarantees, including specific figures and compliance with regulations. It is a specialized opinion or explanation related to financial guarantees, not a full audit report or annual report. It does not contain comprehensive financial statements or detailed audit results but is a standalone explanation related to regulatory requirements. This fits best under Audit Report / Information (AR), which includes standalone audit-related reports and regulatory compliance explanations. FY 2022
2023-04-06 Chinese
海通证券股份有限公司关于迈威（上海）生物科技股份有限公司2022年度持续督导现场检查报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2022年度持续督导现场检查报告" (2022 Annual Continuous Supervision On-site Inspection Report) issued by Haitong Securities as the sponsor institution for Maiwei (Shanghai) Biotechnology Co., Ltd. It references regulatory approvals, continuous supervision period, and detailed findings from an on-site inspection covering governance, internal controls, information disclosure, independence, use of raised funds, related party transactions, and operational status. The document is a detailed report of the sponsor's continuous supervision activities and findings rather than a full annual report or audit report. It is not an announcement or brief notice but a substantive report on the continuous supervision inspection. This type of document aligns with the category of Audit Report / Information (AR), as it is a standalone report related to regulatory compliance and internal control inspection results, not a full annual report or earnings release. The document length (3594 characters) is sufficient for a detailed report but not a full annual report. Therefore, the best classification is AR with high confidence. FY 2022
2023-04-06 Chinese
迈威生物2022年度环境、社会及公司治理报告
Environmental & Social Information Classification · 95% confidence The document is a detailed report from Mabwell Biotech (迈威生物) covering the company's ESG (Environmental, Social, and Governance) activities, corporate governance, management structure, clinical progress, financial data, and other operational highlights for the year 2022. It includes extensive information on company governance, ESG management, clinical trial progress, product commercialization, financial performance, and awards. The document references the 2022 fiscal year and includes comprehensive non-financial and some financial data. It is explicitly described as the company's first annual ESG report and includes governance and sustainability disclosures. The document is lengthy (15,000 characters) and contains substantive content rather than just an announcement or a brief summary. It is not a pure financial report like an Annual Report (10-K) or Interim Report (IR), nor is it a simple announcement or certification. The focus on ESG, governance, and sustainability with detailed disclosures aligns with the category Environmental & Social Information (SR).
2023-04-06 Chinese
迈威生物第一届董事会第二十六次会议决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 26th meeting of the first board of directors of Maiwei (Shanghai) Biotechnology Co., Ltd. It includes approvals of the 2022 annual report, audit report, ESG report, financial statements, profit distribution plan, internal control reports, and other related documents. It also discusses nominations for the second board of directors and proposals to convene the 2022 annual general meeting. The document is not the annual report itself but a formal announcement of board meeting decisions regarding these reports and proposals, many of which will be submitted to the shareholders' meeting for approval. The document length is 4219 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, according to the "Menu vs Meal" rule, this is a Declaration of Voting Results & Voting Rights Announcements (DVA) type document, as it reports on board resolutions and voting outcomes related to annual reports and other corporate governance matters.
2023-04-06 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.